Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.

Oncologist · 2025 · PMC12795601 · PMID 41397917

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significanceP = .052so close (0.05 < p ≤ 0.1)

Regarding sphincter preservation, rates were numerically higher for doublet therapy compared to 5-FU/LV; however, the difference did not reach statistical significance (FOLFIRI vs 5-FU/LV: 81.4% vs 65.5% [ P = .052]; FOLFOX vs 5-FU/LV: 72.4% vs 65.5% [ P = .422]).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.